Cleveland Clinic Study Identifies Factors Associated with Weight Loss Success on Semaglutide or Liraglutide

Researchers found that four in 10 patients (40.7%) were persistent with their medication one year after their initial prescription’s fill. The proportion of patients who were persistent with semaglutide was 45.8% versus 35.6% in patients receiving liraglutide.

WeightControl.com Interview with:
Hamlet Gasoyan, Ph.D.
Lead author of the study and Researcher
Center for Value-Based Care Research
Cleveland Clinic

WeightControl.com:  What is the background for this study? 

Response: Recently, injectable forms of GLP-1 RA medications such as semaglutide have been more commonly prescribed, in part related to their ability to demonstrate clinically significant weight reduction. However, outside of randomized trial settings, data on weight loss with semaglutide or liraglutide for obesity is generally limited to 6 months of follow-up, based on brand names approved by the FDA for type 2 diabetes only, or cohorts that exclude patients who did not persist with the medication.

Last Updated on September 14, 2024 by weightcontrol